DCC 2618

Drug Profile

DCC 2618

Alternative Names: DCC2618

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Deciphera Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Platelet derived growth factor alpha receptor antagonists; Proto-oncogene protein c-kit expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Anaplastic astrocytoma; Gastrointestinal stromal tumours
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Gastrointestinal stromal tumours; Glioblastoma; Systemic mastocytosis

Most Recent Events

  • 09 Sep 2017 Updated efficacy data from a phase I trial in Gastrointestinal stromal tumours presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 05 Sep 2017 DCC 2618 receives Orphan Drug status for Anaplastic astrocytoma in USA
  • 05 Sep 2017 DCC 2618 receives Orphan Drug status for Glioblastoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top